Merck beats Q2 revenue estimates with US$16.61 billion as Keytruda sales rise 5%
AI Market Summary
Merck reported Q2 revenue above consensus, driven by stronger-than-expected Keytruda sales and improving uptake of the subcutaneous QLEX formulation, and lifted its full-year revenue outlook. However, headline results were distorted by large acquisition-related charges that produced a reported net loss and lowered adjusted earnings guidance due to deal expenses. The mix supports pharma fundamentals but tempers near-term risk appetite.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT+3.38%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Merck reported second-quarter revenue of US$16.61 billion, up 5% year on year and above the US$16.36 billion analysts expected, with Keytruda sales rising 5% to US$8.37 billion. The company posted a quarterly loss of 13 cents per share after a US$2.31 per share charge tied to its acquisition of Terns Pharmaceuticals. Animal health revenue rose 8% to US$1.78 billion, slightly ahead of expectations.
